Please login to the form below

Not currently logged in
Email:
Password:

Sun gets FDA marketing nod for Protonix

Sun Pharmaceutical wins FDA approval for its ANDA to market a generic version of Wyeth's Protonix tablets

India-headquartered generic manufacturer Sun Pharmaceutical has won FDA approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Wyeth's Protonix tablets (pantoprazole).

Pantoprazole is indicated for the short-term treatment of erosive esophagitis associated with GERD, maintenance of healing of erosive esophagitis and for the treatment of hypersecretory diseases.

Sun's generic pantoprazole tablets are copies of Wyeth's Protonix Delayed Release Tablets and include 20 mg and 40 mg doses, both of which post annual US sales of around USD 2.3bn.

Sun, which was the first-to-file its generic Protonix ANDA with a Paragraph IV certification, also gains a 180-day marketing exclusivity.

Sun stated that it was now mulling its launch options.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics